

The Essential Biodata Life Science Partner in Rare and Neurodegenerative Diseases

9TH Annual Healthtech Investment Forum

CENTOGENE NV (NASDAQ: CNTG)

September 20, 2022 - Basel

Presenter: Kim Stratton, CEO



Safe Harbour and Disclaimer Statement

This presentation has been prepared by CENTOGENE N.V. (the “Company”), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and neither the delivery of this presentation at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology, such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project” or “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the Company. However, these forward-looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, such as negative economic and geopolitical conditions and instability and volatility in the worldwide financial markets, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company’s own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the Company believes its own internal research is reliable, such research has not been verified by any independent source.

For further information, please refer to the Risk Factors section in our Annual Report for the year ended December 31, 2020, on Form 20-F filed with the SEC on March 31, 2022, and other current reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

Insights to 2,500 Rare and Neurodegenerative to Support Breakthrough Therapies



- Largest Real-World Data Repository for Rare & Neuro Diseases
- Broadest diagnostic testing portfolio for rare diseases
- Accelerate & De-risk from discovery to market access

Bone,
Skin,
Immune

Rare Liver,
Kidney,
Endocrinology
PKD

Rare Hem
HAE

Rare Metabolic Disorders
Fabry disease
Gaucher disease
MPS II
NPC

Malformation
and Retardation

Ophtha

Neurodegenerative Disorders
Parkinson's disease
Friedreich's ataxia
Alzheimer's disease
Frontotemporal dementia
Duchenne muscular dystrophy

GBA-PD

Vascular

Cardio
and Lung

Rare
cancers

Reproductive

ENT



Essential Life Science Partner in Rare and Neurodegenerative Diseases

CENTOGENE




STAKEHOLDER NEEDS

- **Diagnosis** faster than 7yr average wait
- **Acceleration / de-risking** of clinical development stages
- **Access to relevant data** and patients
- **Prove of efficacy** to payors & regulators
- Prediction of **treatment success**
- Justification of **performance-based pricing**



Largest Real-World Data Repository for Rare and Neurodegenerative Diseases



5 Metrics per March 31, 2022. Active Physicians defined as contact with CENTOGENE within the last 5 years, respectively.


Leading, Differentiated Core Products Driving Definitive Diagnosis

Wet-lab: Highly differentiated testing portfolio in state-of-the-art CLIA/CAP certified laboratory **with deep medical expertise**


Gold standard for DNA and multiomic sampling (from >120 countries, **easy logistics** for centralized testing)




Exome testing



Genome testing



Multiomic testing



Dry-lab (SaaS) solution enabling laboratories around the world to deliver leading diagnostic **insights to local patients**



Unique Biopharma Offering

Target & Drug Screening

Patient-derived
Cell Models &
Multiomics

Biomarker/Assay
Identification &
Validation

Clinical Development

Observational Studies

POC/ Ph II/III

Observational
Studies
(e.g., epidemiology,
patient finding,
genetic & biomarker
profiling)

Patient Multiomic
Profiling,
Stratification,
Modelling,
Efficacy Marker

Patient
Identification &
Diagnostics

Market Access & Expansion

RW Registry &
Early Access
Programs

Patient
Stratification,
Genetic &
Biomarker Profiling,
Modelling

Patient ID &
Diagnostics

CENTOGENE Biodata Network

Insight Reports
(e.g., new and existing reports, clinical,
genetic, epidemiology)

Biodata Licenses

Accelerate & De-risk from Discovery to Market Access

Market Access and Expansion: Maximize Access and Personalize Patient, Provider and Biopharma Value

- Real world registry
- Early access programs

- Patient Stratification
- Genetic and Biomarker Profiling
- Modelling

- Patient Identification
- Patient Diagnostics

- CENTOGENE Biodata Network
 - Insight Reports & Biodata Licenses



Rare Metabolic &
Neurodegenerative Diseases
2015-ongoing, 42 countries

Clinical Development: Accelerating and De-risking Clinical Programs

- Observational studies
 - Epidemiology & patient finding
 - Genetic & biomarker profiling

- POC/Ph II/III
 - Patient multiomic profiling
 - Stratification, Modelling, and Efficacy markers
 - Patient identification & diagnostics

- CENTOGENE Biodata Network
 - Insight Reports & Biodata Licenses



Parkinson's disease (PD)
2018-ongoing, 12,500 patients

Target and Drug Screening: Building partnerships around precision and confidence

- Target & Drug Screening
 - Patient-derived cell models & multiomics
 - Biomarker/Assay identification & validation

- CENTOGENE Biodata Network
 - Insight Reports & Biodata Licenses



Gaucher disease
2020-ongoing

Near and Mid Term Priorities

Topline

Growth

- Focus on unique & transformative business model
- Biopharma partnerships: Expand existing and add new with new team
- Dx: Geo Focus, Multiomics & CentoCloud to grow above-market level

2022 Guidance:*

Revenues
~50-52 € million

**+15-20%
YoY**

Bottomline

Cost management

- Drive fit-for-purpose organization
- Focus on efficient operations and margin improvement

Q1
2022

€ 10.3M up +3% yoy
acceleration in 2H22 driven
by biopharma

Runway

Cashflow

- Sector is not about growth at all costs
- Diligently manage cash and extend runway

\$

\$62M financing (~€55M) in
Q1 2022: €15M PIPE & \$45M
secured debt facility **



Thank you